Experimental drug AK-1286 for advanced solid tumors
Part of Cancer clinical trials.
This study tests a new experimental drug called AK-1286 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the drug is safe and may help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old.
- Have an advanced solid tumor (cancer that started in an organ or tissue) that has stopped responding to standard treatments or you can't tolerate them.
- Have a doctor-confirmed measurable tumor for the expansion part of the study.
- Be expected to live at least 3 more months.
- Be able to take care of yourself (ECOG score 0 or 1) and have adequate organ function (like blood counts, kidney, liver).
- If you're of childbearing age, agree to use effective birth control and have a negative pregnancy test (if female).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
This trial tests a new drug called AK131 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and can help slow or shrink the cancer.
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
This trial tests a new drug called AK138D1 for people with advanced solid tumors that have not responded to or can't tolerate standard treatments. The goal is to see if it is safe and effective.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.